Subha Saha

About

Through the course of my education and academic career I have built an extensive background in basic and translational research. My overachieving goal is to continue pursuing translational hemato-oncological research through integrative approaches; and identify selective dependencies/combinations for targeting and improved disease management. During my Ph.D. at Institute of Life Sciences, India I focused on how chromatin remodelers shape myeloid differentiation landscape and their dysregulation contribute to leukemogenesis. We found, SMARCD1 an auxiliary subunit of the ATP-dependent SWI/SNF chromatin remodeling complex is highly enriched in the hematopoietic and leukemic stem/progenitor cells. Using challenging genetic manipulation strategies in cell lines and primary patient samples, we found SMARCD1 is necessary to maintain self-renewal/ proliferation in leukemic stem cells. Through molecular biology and NGS approaches we confirmed, SMARCD1 binds to the promoters of differentiation genes and maintains a repressive chromatin state, obligating a differentiation block. This is a potential lead information to support the usage of inhibitors targeting the SWI/SNF complex (which are known to induce differentiation) in AML. In my current post-doctoral training in Dr. Peter Miller’s lab at Massachusetts General Hospital and Harvard Medical School, I am expanding my expertise and skill sets to gain deep insights into Menin inhibitor responses in acute myeloid leukemia.

Employment

• Broad Institute of MIT and Harvard
  2023 - Present
• Massachusetts General Hospital Postdoc
  2023 - Present
• Institute of Life Sciences Senior Research Fellow
  2018 - 2022
• Institute of Life Sciences Senior Research Fellow
  2016 - 2022
• Institute of Life Sciences Junior Research Fellow
  2016 - 2018

Education

• RCB Ph.D.
  2016 - 2022

Projects & Funding

Projects & funding information is unavailable.

Publications

Publications are unavailable.